Business
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT
About this update from Clene Inc.
[{"type":"image","alt":"Clene Inc.","displaySize":"","headline":null,"caption":"Clene Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dqllcqG43QFquU0vfLNVhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188","width":300,"height":72}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activity","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Company has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathway","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene is hosting an investor webcast today at 8:30 am ET","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced completion of the FDA-recommended biomarker analyses for CNM-Au8® in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) and provide compelling evidence linking biomarker decline to improved survival.","length":711,"tagName":"p"},{"type":"text","content":"“We followed the FDA’s roadmap — and the data delivered,” said Rob Etherington, President and CEO of Clene. “Statistically significant NfL reductions in more advanced real-world ALS patients; a second independent disease-specific biomarker (GFAP) ...